New National Sales Manager for Uniferon®

January 4, 2013

Announcing our new National Sales Manager in US for Uniferon® Mr. Jimmy Heisel.

Uniferon was introduced in the US in 2011 and it has become a world leading Iron Injectable product for piglets. It is the goal of Pharmacosmos to establish a stronger market position in US for Uniferon® in 2013 and in the years to come.

Pharmacosmos is excited to announce that Mr. Jimmy Heisel will be joining our US team at Pharmacosmos Inc., New Jersey, as National Sales Manager for Uniferon starting January 1, 2013.

Jimmy comes from a successful position as Senior Sales Representative at Abbott Animal Health, a division of Abbott Laboratories. He has expertise in product marketing with strong commitment of enforcing Uniferon's US market position and generating sustained, profitable sales growth of the product.  We believe these skills will make Jimmy a valuable addition to our team

Pharmacosmos'   collaboration with partner accounts, and Ivesco as preferred distribution partner, has generated impressive results.  It is Jimmy's role to establish and retain long-term relationships with partners, swine producers and veterinarians.  He will also focus his efforts on facilitating information on best quality procedures on Anaemia Management as practiced by globally leading swine producers and veterinarians.

Pharmacosmos looks forward to strengthen its US operations with the addition of Jimmy Heisel as the National Sales Manager.  The transition and integration of a full-time Sales Manager will reinforce our commitment to top-notch customer service and awareness on the importance of Uniferon in the Swine Industry.

Mr. Arnold Baker, our US Business Consultant, has been a tremendous asset on the introduction and marketing of Uniferon in the US.  We thank him for his efforts and direction.

"We look forward to welcoming Jimmy as a pivotal part of our global Uniferon team. We see Jimmy's joining our company as a natural next step in our penetration of the US market said Jens Fabricius, Vice President, Marketing & Business Operations at Pharmacosmos A/S".

"Uniferon has undoubtedly experienced a most remarkable and impressive entry onto the US market and Uniferon is today top of shelf almost anywhere. My vow is to expand this position and make Uniferon top of mind as well, enforcing the brand's position in order to generate additional sales," said Jimmy Heisel.

"I look forward to expand nationwide personal service and support direct to swine producers and veterinary clinics in the area of Anaemia Disease Management," said Jimmy Heisel.

Pharmacosmos is dedicated to developing and marketing leading iron deficiency treatments for both humans and animals. The company focuses on researching and improving treatment options by building on industry best practices. Pharmacosmos has an extensive network of partners in more than 50 countries across Europe, the Americas and Asia.

Thank you for welcoming Mr. Jimmy Heisel.

About Uniferon

Uniferon is a modern improved iron hydrogenated dextran based on a natural formula, which is approved for global use:

Uniferon is manufactured without the use of any organic solvents or cyanide, thus, avoiding trace residues of these impurities. Pharmacosmos manufactures iron dextran of high quality and unique purity for customers worldwide. Uniferon is the only injectable iron brand for piglets approved in the EU, the US and Asia.

About Pharmacosmos

Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.

A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.

Pharmacosmos has subsidiaries in the Nordics, the UK and the US and its products are marketed in more than 80 countries across the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.